The CREATE-X trial demonstrated that disease-free survival (DFS) was significantly prolonged with adjuvant capecitabine use in HER2-BC patients (especially in TNBC patients) who had a residual invasive disease (non-pCR) after standard NACT [16]. Here, ERBB2 is linked to breast cancer.